Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECT ...

[Full Year 2023 Financial Results and Corporate Update](index=1&type=section&id=Addex%20Therapeutics%20Reports%20Full%20Year%202023%20Financial%20Results%20and%20Provides%20Corporate%20Update) Addex Therapeutics reported full-year 2023 financial results, emphasizing Neurosterix launch, operational milestones, and improved financial performance [Introduction and CEO Remarks](index=1&type=section&id=Introduction%20and%20CEO%20Remarks) Addex Therapeutics announced 2023 financial results, emphasizing the transformational Neurosterix launch and key upcoming milestones - The launch of Neurosterix, in collaboration with Perceptive Advisors, is considered a **transformational transaction** for Addex, validating decades of work[3](index=3&type=chunk) - Top-line data from the ADX71149 Phase 2 epilepsy study is anticipated by **mid-May 2024**[1](index=1&type=chunk)[3](index=3&type=chunk) - The company plans to start IND-enabling studies for drug candidates from its GABAB PAM collaboration with Indivior by the **end of 2024**[3](index=3&type=chunk) [Operating Highlights](index=1&type=section&id=Operating%20Highlights) Key operational milestones in 2023 include the Neurosterix launch, extended Indivior collaboration, and preclinical program advancements - Launched Neurosterix with Perceptive Advisors, securing **USD 63 million** to advance the allosteric modulator drug discovery platform and unpartnered preclinical portfolio[1](index=1&type=chunk)[4](index=4&type=chunk) - The GABAB PAM collaboration with Indivior for substance use disorders was extended to the **end of June 2024**, with an additional **CHF 2.7 million** in research funding[4](index=4&type=chunk) - An Addex-led consortium secured a **EUR 4 million** Eurostars grant for its mGlu2NAM mild neurocognitive disorders discovery program[4](index=4&type=chunk) - Data supporting the development of dipraglurant in post-stroke recovery was published in the journal *Brain*[4](index=4&type=chunk) [Financial Performance](index=1&type=section&id=Financial%20Performance) Addex significantly reduced 2023 operating and net losses, driven by decreased R&D and G&A expenses Key Financial Data (CHF in thousands) | Financial Metric | 2023 | 2022 | Change | | :--- | :--- | :--- | :--- | | Income | 1,647 | 1,445 | 202 | | R&D expenses | (6,962) | (14,665) | 7,703 | | G&A expenses | (4,966) | (7,300) | 2,334 | | Total operating loss | (10,281) | (20,520) | 10,239 | | Net loss for the period | (10,556) | (20,804) | 10,248 | | Basic and diluted net loss per share (CHF) | (0.14) | (0.46) | 0.32 | | Cash and cash equivalents | 3,865 | 6,957 | (3,092) | - R&D expenses decreased by **CHF 7.7 million** to **CHF 7.0 million** in 2023, mainly due to reduced external R&D activities related to dipraglurant[7](index=7&type=chunk) - G&A expenses fell by **CHF 2.3 million** to **CHF 5.0 million** in 2023, primarily due to lower share-based service costs and D&O insurance costs[7](index=7&type=chunk) - The net loss decreased by **CHF 10.2 million**, largely as a result of the reduction in R&D expenses[7](index=7&type=chunk) - Cash and cash equivalents decreased by **CHF 3.1 million**, reflecting cash used in operations, partially offset by proceeds from a **USD 5 million** equity offering in April 2023 and research funding from Indivior[7](index=7&type=chunk) [Corporate Information](index=2&type=section&id=Corporate%20Information) Addex Therapeutics, a clinical-stage biopharmaceutical company, provided corporate details and forward-looking statements - Addex is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders[11](index=11&type=chunk) - The company's lead drug candidate is ADX71149 for epilepsy, followed by dipraglurant for Parkinson's-related dyskinesia and post-stroke recovery[11](index=11&type=chunk) - A conference call and webcast to review the financial results was scheduled for **April 18, 2024**, with registration details provided[9](index=9&type=chunk)[10](index=10&type=chunk) - The press release contains forward-looking statements, and actual results may differ materially due to various risks and uncertainties detailed in the company's SEC filings, including the Annual Report on Form 20-F[13](index=13&type=chunk)

Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery ...

Core Points - Addex Therapeutics will release its Full-Year 2023 Financial Results on April 18, 2024, with a teleconference and webcast for stakeholders [1] - The company focuses on developing allosteric modulators for neurological disorders, with key drug candidates in various stages of clinical development [3] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, ADX71149, is in a Phase 2 clinical study for epilepsy, developed in collaboration with Janssen Pharmaceuticals [3] - The second clinical program, dipraglurant, is being evaluated for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior to advance multiple drug candidates for substance use disorder and is also developing a GABAB PAM program for chronic cough [3] - The company holds a 20% stake in Neurosterix LLC, which is advancing several allosteric modulator programs for various neurological conditions [3] Upcoming Events - A business update and product pipeline review will be provided by CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev during the teleconference on April 18, 2024 [1]

Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 0 ...

Addex receives CHF5M and 20% share of Neurosterix  Perceptive Advisors leads $63M investment into Neurosterix  Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to Neurosterix Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, and funds affiliated ...

Core Insights - Addex Therapeutics is a clinical-stage pharmaceutical company focused on allosteric modulation-based drug discovery and development [2] - The company will present a corporate update at the Bio-Europe Spring 2024 conference in Barcelona, Spain, from March 18-20, 2024 [1] Company Overview - Addex Therapeutics specializes in developing novel orally available small molecule drugs known as allosteric modulators for neurological disorders [2] - The lead drug candidate, ADX71149, is a positive allosteric modulator (PAM) for mGlu2 and is currently in Phase 2 clinical trials for epilepsy [2] - The second clinical program, dipraglurant, is a negative allosteric modulator (NAM) for mGlu5, under evaluation for post-stroke recovery [2] - Indivior PLC has licensed Addex's GABAB PAM program for substance use disorder development [2] - The company is advancing a preclinical pipeline targeting various conditions, including chronic cough, stress-related disorders, schizophrenia, and mild neurocognitive disorders [2] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [2]

Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024. In his presentation, Dr Lütjens will provide a corporate update and discuss recent advances from Addex's CNS pipeline. Presentation Details:Date: T ...

Company Overview - Addex Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing allosteric modulators for neurological disorders [2] - The company’s lead drug candidate, ADX71149, is a positive allosteric modulator in Phase 2 clinical trials for epilepsy [2] - Addex is also advancing a preclinical pipeline targeting various neurological conditions, including chronic cough, stress-related disorders, schizophrenia, and mild neurocognitive disorders [2] Recent Developments - Dr. Robert Lütjens, Head of Discovery - Biology, will present a corporate update and discuss advances in Addex's CNS pipeline at the Swiss Equities Baader Conference from January 10-12, 2024 [1] - The presentation is scheduled for January 11, 2024, at 16:20 CET in Bad Ragaz, Switzerland [1] Collaboration and Licensing - Indivior PLC has licensed Addex's GABAB PAM program for developing drug candidates focused on substance use disorder [2] - The collaboration with Janssen Pharmaceuticals for ADX71149 highlights Addex's strategic partnerships in drug development [2]

Core Insights - Addex Therapeutics is a clinical-stage pharmaceutical company focused on allosteric modulation for neurological disorders, with a pipeline that includes several promising drug candidates [2] Group 1: Corporate Update - CEO Tim Dyer will present at the Biotech Showcase in San Francisco on January 8, 2024, discussing recent advances in Addex's CNS pipeline [1] - The presentation will cover key programs including ADX71149 for epilepsy, dipraglurant for post-stroke recovery, and partnerships for substance use disorders [1][2] Group 2: Pipeline Overview - ADX71149 is currently in Phase 2 clinical trials for epilepsy in collaboration with Janssen Pharmaceuticals [2] - Dipraglurant is being evaluated for post-stroke recovery, while the GABAB PAM program has been licensed to Indivior for substance use disorder treatment [2] - The company is also advancing preclinical programs targeting chronic cough, stress-related disorders, schizophrenia, and mild neurocognitive disorders [2]